Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
MINNEAPOLIS, April 10, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
MINNEAPOLIS, April 10, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or…
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or…
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical…
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical…
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting
BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting
BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to…
Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to…
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers…
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers…